GE HealthCare Advances Imaging Portfolio with AI Ultrasounds and Distribution Deal

GE HealthCare Introduces Advanced AI Ultrasound Systems and Expands Imaging Agent Reach

GE HealthCare Technologies (GEHC) has announced the launch of new artificial intelligence (AI)-enabled ultrasound systems for cardiovascular and women's health, alongside a strategic U.S. distribution agreement for its novel cardiac PET imaging agent, Flyrcado (flurpiridaz F18) injection. These initiatives signal the company's intensified focus on integrating AI across diagnostic pathways and expanding its market presence in specialized medical imaging.

Key Product Launches and Strategic Distribution

In late August 2025, GE HealthCare unveiled the Vivid Pioneer, an AI-powered cardiovascular ultrasound system that received both CE Mark and U.S. FDA 510(k) clearance. This system is designed to enhance cardiovascular diagnostics, notably reducing exam times by 30% and inter-operator variability by 40% through automated strain analysis and 4D imaging. It also features AI performance that is 360% faster than previous models. Following this, in September 2025, the company introduced the Voluson Performance 18 and 16, new AI-enabled ultrasound systems specifically for women's health, which also secured FDA 510(k) clearance and CE Mark approval. These launches underscore GE HealthCare's commitment to leveraging AI to improve workflow efficiency and diagnostic precision.

Further bolstering its portfolio, GE HealthCare entered into a Distribution and Services Agreement (DSA) with CardioNavix, a division of CDL Nuclear Technologies, in September 2025. This agreement aims to broadly distribute Flyrcado, a cardiac PET imaging agent, across the U.S., targeting private cardiology practices, office settings, and hospitals. This expansion is critical as PET MPI procedures are increasingly utilized, with CardioNavix supporting approximately 220,000 cardiac PET procedures annually through its extensive network of nearly 225 U.S. customers. The multi-center international Phase III AURORA trial demonstrated Flyrcado's higher diagnostic efficacy compared to SPECT MPI for detecting coronary artery disease, positioning it for accelerated adoption.

Market Response and Valuation Insights

GE HealthCare's stock performance has shown mixed trends. While the share price declined nearly 17% year-over-year, it recorded a 5% gain over the past three months, signaling renewed investor interest following these strategic announcements. Simply Wall St's analysis suggests GEHC is currently 14.9% undervalued, with a fair value estimated at $88. This assessment is based on growth projections, despite the stock trading at 39.4% below their fair value estimate. Earnings are forecast to grow by 4.52% annually, building on a 41.4% growth over the past year.

Financially, GE HealthCare reported Q2 2025 revenue of $5 billion, a 3% year-over-year increase, with an adjusted EBIT margin of 14.6% and diluted EPS of $1.06. Another report cited Q2 2025 revenue at $5.25 billion, a 7% year-over-year increase, with an adjusted EPS of 97 cents. For Q1 2025, total revenue increased 2.7% year-over-year to $4.8 billion, with an adjusted EBIT margin expanding to 15% and adjusted EPS rising 12.2% to $1.01, surpassing Street forecasts. The company has also raised its 2025 guidance, projecting organic revenue growth of approximately 3% and adjusted EPS of $4.43–$4.63, despite a $0.45 tariff impact, which is lower than previously expected due to mitigation efforts.

Broader Market Context and Strategic Implications

The strategic focus on AI-driven diagnostics aligns with significant market trends. The AI-driven cardiology market is projected to grow at a robust 46.1% CAGR from 2024 to 2029, potentially reaching $10.38 billion. Similarly, the U.S. AI in medical imaging market is expected to reach $2.93 billion by 2030. These advancements are crucial in addressing challenges such as clinician burnout and the need for improved diagnostic accuracy. GE HealthCare has maintained its leadership in AI-enabled medical devices, topping the U.S. Food and Drug Administration's list for the fourth consecutive year with 100 authorizations, with an aim to double this to over 200 by 2028. This leadership is further bolstered by acquisitions, such as the Intelligent Ultrasound Group PLC's clinical AI software business for $51 million in October 2024, integrating ScanNav Assist AI technology into its ultrasound devices. The company's Pharmaceutical Diagnostics segment reported a 14% revenue growth in Q2 2025, driven by demand for Flyrcado and other radiopharmaceuticals.

Analyst Sentiment and Forward Outlook

Analyst consensus for GEHC is a "Buy" rating as of September 15, 2025, based on evaluations from 16 analysts. The average price target is set at $92.31. While some analysts anticipate a 10.5% year-over-year decline in adjusted earnings for the full fiscal year 2025, they project GE HealthCare Technologies to achieve $22.7 billion in revenue and $2.5 billion in earnings by 2028, assuming a steady annual revenue growth rate of 4.3%.

"This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care," said Eric Ruedinger, vice president and general manager of GE HealthCare's Pharmaceutical Diagnostics division for the U.S. and Canada.

Looking ahead, GE HealthCare's continued investment in AI integration, expansion through partnerships, and mitigation of tariff impacts are key factors to watch. The company expects a lower profit impact from tariffs in 2026 compared with 2025 due to ongoing supply chain restructuring. Despite positive prospects in AI and specialized diagnostics, potential challenges remain, including ongoing tariff pressures and regulatory uncertainties, particularly in major markets such as China, where the company has seen declining sales.